SCHEMBL19206316

SCHEMBL19206316

Cn1c(=O)n(Cc2ccc(F)cc2)c(=O)c2cc(C(=O)c3nc(-c4cn[nH]c4)c4ccccn34)ccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.41
SLC22A8 Q8TCC7 1/20 0.41
HDAC1 Q13547 5/20 0.40
HDAC11 Q96DB2 4/20 0.40
HDAC8 Q9BY41 4/20 0.40
HDAC6 Q9UBN7 4/20 0.40
HPD P32754 2/20 0.39
PARG Q86W56 2/20 0.38
PKM P14618 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
ROCK2 O75116 2/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
USP1 O94782 2/20 0.36
RORC P51449 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15016914 0.87 MMP13 (0.41) MMP13SLC22A8HDAC1HDAC11HDAC8
SCHEMBL14916111 0.87 PKM (0.44) MMP13SLC22A8HDAC1HDAC11HDAC8
Hydrochloric Acid SCHEMBL14916909 0.87 PKM (0.44) MMP13SLC22A8HDAC1HDAC11HDAC8
SCHEMBL322594 0.86 MMP13 (0.46) MMP13SLC22A8HDAC1HDAC11HDAC8
SCHEMBL322222 0.85 HDAC1 (0.41) MMP13SLC22A8HDAC1HDAC11HDAC8
SCHEMBL15094059 0.84 KDM4E (0.40) MMP13SLC22A8HDAC1HDAC11HDAC8
SCHEMBL14916199 0.84 MMP13 (0.47) MMP13SLC22A8HDAC1HDAC11HDAC8
SCHEMBL15016935 0.84 MMP13 (0.41) MMP13SLC22A8HDAC1HDAC11HDAC8
SCHEMBL15093749 0.82 HDAC1 (0.42) HDAC1HDAC11HDAC8HDAC6HPD
SCHEMBL15093892 0.82 HDAC1 (0.39) MMP13SLC22A8HDAC1HDAC11HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170231998-A1 Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof SANOFI (FR) 2017-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170231998-A1 Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof FGF1, FGF2, FGFR1 MMP13 1510/4885SLC22A8 1571/4885HDAC1 2258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.